All Digests

June 18, 2026 7 stories

CordenPharma's AmbioPharm Subsidiary $120M Aiken County Peptide Expansion, Barclays Lifts Hims & Hers PT $29→$39 on Peptide Catalyst, Frontiers Cell-Penetrating Peptide Diabetes Delivery Paper, PCAC + 503B Deadlines 11-12 Days Out, AHA/ACC First-Ever CKM Syndrome Guideline, Ohio State Board Peptide Compounding Guidance, Hanmi HM500197 First Peptide-Based Myostatin Inhibitor at ADA 2026

AmbioPharm $120M SC peptide expansion, Barclays raises Hims to $39, Frontiers CPP diabetes delivery, PCAC/503B 11-12 days, AHA/ACC CKM guideline, Ohio + Hanmi.

Read digest →

June 17, 2026 6 stories

D&D Pharmatech + LG AI Research Peptide AI Partnership, Bloomberg Businessweek Peptide Gold Rush Feature, UCSD Semaglutide Epigenetic Aging Nature Communications, Azitra Cosmetic Peptide BIO 2026, Annals of Oncology 41% GLP-1 Cancer Risk Cut, Alabama Board Bans Research-Grade Peptides

D&D + LG AI lifts D&D 17%, Bloomberg gold-rush, UCSD semaglutide aging slowdown, Azitra +87%, Annals 41% cancer cut, Alabama bans research peptides.

Read digest →

June 16, 2026 5 stories

MultiValent Biotherapies $27M Series A for Prostate Cancer PDC, Tirzepatide PNAS Nexus Real-World Beats Semaglutide, JAMA Viewpoint on Online Peptide Regulation Gap, Business Group on Health: 10% of Employers Plan to Drop GLP-1 in 2027

MVB-101 PSMA × FRα prostate PDC launches with $27M, PNAS Nexus tirzepatide vs semaglutide real-world, JAMA viewpoint on online peptides, employer GLP-1 drop.

Read digest →

June 15, 2026 5 stories

Entera EB613 Single-Tablet ENDO 2026 Matches Forteo, Rhythm Setmelanotide PWS + Hypothalamic Obesity + BBS, Crinetics Atumelnant Phase 2 CAH, Neurocrine Crenessity Pediatric 2-Year, 503B Window 14 Days

ENDO 2026 day 3: Entera EB613 single-tablet matches Forteo; Rhythm setmelanotide across PWS, AHO, BBS; Crinetics atumelnant CAH; Neurocrine Crenessity year 2.

Read digest →

June 14, 2026 5 stories

Crinetics Palsonify 2-Year OLE at ENDO 2026, GLP-1 Patients Walk 560 Fewer Steps, Semaglutide Cuts Fractures 15%, Ascendis TransCon CNP 2-Year ApproaCH, GLP-1s and Male Fertility

ENDO 2026 day 2: Crinetics Palsonify 2-yr OLE confirms acromegaly control; GLP-1 secondary effects on activity, fractures, fertility; TransCon CNP year 2.

Read digest →

June 13, 2026 5 stories

ENDO 2026 Opens in Chicago, Ascendis TransCon PTH 5-Year 82% Response, Crinetics Palsonify 2-Year OLE Sunday, Entera EB613 Oral PTH Late-Breaker, Rusfertide EHA 2026 Long-Term

ENDO 2026 opens with PTH peptide showdown (Ascendis 82% 5-yr, MBX canvuparatide, Entera EB613); Crinetics Palsonify 2-yr OLE Sunday; rusfertide EHA 2026.

Read digest →

June 12, 2026 5 stories

Camurus Oclaiz Second Manufacturing CRL, MBX Canvuparatide Phase 2 + 1-Year OLE Hit, AJMC GLP-1 Emerging Indications, Parabilis $670M IPO Debut, The Hill on MAHA Peptide Push

Camurus second CRL on Oclaiz, MBX canvuparatide Phase 2 + 1-yr data set up Q3 Phase 3, Parabilis breaks IPO record at $670M, AJMC quantifies GLP-1 indication creep.

Read digest →

June 11, 2026 5 stories

Wegovy Pill UK MHRA Approval Today, Novartis Del-Brax FSHD Biomarker Hit, Wegovy Pill UAE Launch, Moes Group GHK-Cu Private-Label Manufacturing

Novo Wegovy pill clears UK MHRA today, Novartis del-brax met FSHD biomarker primary, Wegovy pill launched UAE June 3, Moes Group enters GHK-Cu OEM.

Read digest →

June 10, 2026 7 stories

Camurus Oclaiz PDUFA Day, Wegovy Pill 3M Scripts in 5 Months, Lantheus PNT2003 30-Month Stay Expires, Peptide Industry Federal Enforcement Watch

PDUFA day for Camurus Oclaiz octreotide depot, Wegovy pill hits 3M US scripts in 5 months, Lantheus PNT2003 stay expires, and the peptide-enforcement watch.

Read digest →

June 9, 2026 8 stories

Pfizer Berobenatide Monthly GLP-1 15.9% Phase 2b, Retatrutide Dysesthesia 20.9% at 12 mg, ADA Post-Mortem: Lilly Dominant, Roche Me-Too, Novo Pressured, Pharmacy Times Peptide Compounding Analysis

Post-ADA: Pfizer's monthly berobenatide hits 15.9%, retatrutide's dysesthesia signal sharpens to 20.9% at 12 mg, analysts read Lilly dominant and Roche me-too.

Read digest →

June 8, 2026 10 stories

ADA 2026 Closes: Orforglipron ACHIEVE Beats Oral Semaglutide Head-to-Head, AstraZeneca Elecoglipron 10.5% Phase 2b + Lancet, Roche Enicepatide 22.5%, Boehringer Survodutide Fat-Loss Detail, Petrelintide Tolerability

ADA closes: orforglipron beats oral semaglutide head-to-head, elecoglipron 10.5%, Roche enicepatide 22.5%, survodutide fat-loss detail, plus new SoC.

Read digest →

June 7, 2026 8 stories

ADA 2026 Day 3: CagriSema REIMAGINE 1/2/3 Lancet Publication, Mazdutide GLORY-2 + DREAMS-3 Beats Semaglutide, Novo Zenagamtide 14.6%, Elecoglipron China Phase 1b, MetaVia + Lexicon

ADA Day 3: REIMAGINE 1/2/3 publishes in Lancet, mazdutide beats semaglutide head-to-head, zenagamtide hits 14.6% in T2D, elecoglipron and MetaVia add detail.

Read digest →

June 6, 2026 6 stories

ADA 2026 Day 2: Retatrutide TRIUMPH-1 Full Data + Lancet TRANSCEND-T2D-1, TRIUMPH-4 OA + TRIUMPH-3 OSA, Arrhythmia Safety Signal, ADA Obesity Standards of Care 2026

ADA Day 2: full retatrutide TRIUMPH-1 + TRIUMPH-4 data, Lancet publishes TRANSCEND-T2D-1, an arrhythmia signal, plus the ADA Obesity Standards of Care.

Read digest →

June 5, 2026 10 stories

ADA 2026 Day 1: Structure Aleniglipron Nature Medicine + Oral, CagriSema REIMAGINE 2 14.2% T2D, MetaVia DA-1726 32mg, Hengrui HRS-7535 Phase 3, Survodutide SYNCHRONIZE-1, Lexicon Sotagliflozin

ADA opens: Structure aleniglipron in Nature Medicine, CagriSema REIMAGINE 2 14.2% T2D loss, survodutide SYNCHRONIZE-1, Hengrui HRS-7535, MetaVia, Lexicon.

Read digest →

June 4, 2026 6 stories

Parabilis $476M Peptide IPO, Petrelintide ZUPREME-1 Amylin Data, Survodutide SYNCHRONIZE-1 Obesity, Verdiva Amylin Pipeline, AstraZeneca Elecoglipron, ADA 2026 Eve

ADA's eve: Parabilis prices a $476M peptide IPO, plus pre-conference data from petrelintide, survodutide, Verdiva, and elecoglipron.

Read digest →

June 3, 2026 4 stories

Novo CagriSema + Zenagamtide ADA Slate, Structure Aleniglipron Oral GLP-1, EPFL Membrane-Permeable Cyclic Peptides, ADA 2026 Eve

Two days before ADA 2026: Novo's CagriSema and zenagamtide slate, Structure's oral aleniglipron, an EPFL cyclic-peptide advance, and the field preview.

Read digest →

June 2, 2026 6 stories

BPC-157 Evidence Investigation, MC4R-Deficiency GLP-1 Comparison, Sapience Lucicebtide ASCO Final Data, ADA 2026 Curtain-Raiser, Camurus Oclaiz June 10 PDUFA

A STAT/Undark BPC-157 evidence probe, an MC4R-deficiency GLP-1 comparison, Sapience's lucicebtide ASCO data, the ADA 2026 preview, and Camurus' June 10 PDUFA.

Read digest →

June 1, 2026 7 stories

Bicycle Duravelo-2 Urothelial Data, Mayo TPIV200 Vaccine Phase 2, Avacta Faridoxorubicin, Pfizer Sigvotatug ADC, Lilly ADA Retatrutide Slate, Syneron $150M Peptide Raise

ASCO's biggest peptide-oncology day: Bicycle, Mayo TPIV200, Avacta and Pfizer sigvotatug, plus Syneron's $150M peptide raise and Lilly's ADA slate.

Read digest →